Adaptor protein-2 associated kinase 1 (AAK1) is key in clathrin-mediated endocytosis, which diverse viruses hijack in order to infect cells. Inhibiting AAK1 has been shown to block the entry of hepatitis C, dengue and rabies viruses into cells.
Work at Satellos Bioscience Inc. has led to the identification of new AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of muscular dystrophy.
For executives of Lexicon Pharmaceuticals Inc., the missed primary endpoint in the phase IIb Progress study testing pilavapadin, its non-opioid candidate, in adults with moderate to severe diabetic peripheral neuropathic pain seemed merely a footnote for what CEO Mike Exton called an “exciting and long-awaited day for the Lexicon team, collaborators and patients.”
Jiangsu Alicorn Pharmaceutical Co. Ltd. has described AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s disease, schizophrenia, diabetic peripheral neuropathy and postherpetic neuralgia.
Satellos Bioscience Inc. has developed and presented data for a compound that targeted the process of muscle regeneration based on modulation of satellite stem cell polarity.
Satellos Bioscience Inc. recently presented preclinical data for the novel oral small-molecule AP2-associated protein kinase 1 (AAK1) inhibitor SAT-3247, being developed for the treatment of Duchenne muscular dystrophy and other muscle degenerative diseases, at the Muscular Dystrophy Association conference.
Humanwell Healthcare (Group) Co. Ltd. researchers have prepared and tested AP2-associated protein kinase 1 (AAK1) inhibitors that are reported to be useful for the treatment of bipolar disorder, pain, schizophrenia, Alzheimer’s and Parkinson’s disease.
Sichuan Haisco Pharmaceutical Co. Ltd. has disclosed AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of diabetic neuropathy and postherpetic neuralgia.
